Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Innovation ETF (ARKK) vs ResMed Inc. (RMD) Price & Performance

ARK Innovation ETFTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

ARK Innovation ETF vs ResMed Inc. — how do they compare? ARK Innovation ETF trades at $81.41, while ResMed Inc. trades at $226.1 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while ARK Innovation ETF pays none, and ARK Innovation ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.

ARKKRMD
52-Week High
$92.50$293.73
52-Week Low
$63.52$182.82
Market Cap
$32.61B
Sector
Health
Enterprise Value
$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Innovation ETF

ARKK trades at $81.22, up 0.94% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF's concentrated portfolio in disruptive innovation faces mixed sentiment, with recent news highlighting both buying activity in AI stocks like CoreWeave and concerns over high fees and underperformance versus the S&P 500. Key resistance is at $82, with support at $79.

Outlook remains volatile; ARKK offers exposure to high-growth themes like AI and space technology but carries significant concentration risk and fee drag. Investment opportunity hinges on successful bets in unprofitable ventures, while risks include dependency on Tesla and SpaceX performance and broader market shifts away from speculative growth.

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Returns comparison

Trailing returns across standard periods

About ARK Innovation ETF

The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.

Read more on ARKK

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD